M. Plets

发表

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

I. Thompson, C. Tangen, B. Shuch, 2021, The Lancet.

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

I. Thompson, C. Tangen, N. Agarwal, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT039: A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort

Helen X. Chen, Preet Paul Singh, R. Kurzrock, 2019, Clinical Trials.

A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort

Helen X. Chen, R. Kurzrock, C. Ryan, 2021, Cancer.

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Helen X. Chen, Preet Paul Singh, R. Kurzrock, 2020, Clinical Cancer Research.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

I. Thompson, C. Tangen, M. Carducci, 2018, Cancer treatment and research communications.

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction

I. Thompson, N. Agarwal, N. Mitsiades, 2017, JAMA oncology.

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

R. Gray, S. Adams, R. Kurzrock, 2021, Clinical Cancer Research.

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer

I. Thompson, C. Tangen, M. Tewari, 2018, The Prostate.

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Jared S. Fowles, I. Thompson, C. Tangen, 2021, Clinical Cancer Research.

A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.

I. Thompson, C. Tangen, B. Shuch, 2017 .

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.

I. Thompson, C. Tangen, M. Lucia, 2019, Journal of Clinical Oncology.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial

E. Messing, I. Thompson, C. Tangen, 2018, JAMA.

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

W. Lowrance, I. Thompson, C. Tangen, 2020, Journal of Clinical Oncology.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

R. Kurzrock, C. Blanke, S. Nair, 2021, Journal for ImmunoTherapy of Cancer.

SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.

Helen X. Chen, R. Kurzrock, C. Ryan, 2019, Journal of Clinical Oncology.

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

R. Gray, S. Adams, R. Kurzrock, 2020 .

Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

T. Flaig, M. Plets, Peter J. Boxley, 2020, Bladder cancer.

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Michael R. Wagner, R. Kurzrock, S. Nair, 2020 .

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421

G. Pond, I. Thompson, C. Tangen, 2017, Clinical genitourinary cancer.

Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).

J. Pinski, S. Ingles, I. Thompson, 2016 .

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

M. Meng, I. Thompson, C. Tangen, 2019, Kidney Cancer.

INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.

I. Thompson, C. Tangen, B. Costello, 2021, Journal of Clinical Oncology.

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Jared S. Fowles, I. Thompson, C. Tangen, 2022, Journal of Clinical Oncology.

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

I. Thompson, C. Tangen, N. Agarwal, 2017, Kidney cancer.

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.

I. Thompson, K. Siegmund, A. Goldkorn, 2022, European urology oncology.

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).

Jared S. Fowles, I. Thompson, C. Tangen, 2023, European urology.

S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.

I. Thompson, M. Lucia, D. McConkey, 2017 .

SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC).

I. Thompson, C. Tangen, N. Agarwal, 2015 .

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

J. Pinski, S. Ingles, I. Thompson, 2021, Clinical Cancer Research.

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

I. Thompson, C. Tangen, N. Agarwal, 2022, Journal of Clinical Oncology.

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

W. Lowrance, I. Thompson, C. Tangen, 2023, European Urology.

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.

K. Siegmund, A. Goldkorn, D. McConkey, 2023, European urology oncology.

Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.

A. Alva, G. Bjarnason, N. Balzer-Haas, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

P. Humphrey, C. Tangen, B. Shuch, 2021 .